Mechanical strabismus

Summary

Mechanical strabismus (MONDO:0004753) is a disease. A subtype of strabismus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mechanical strabismus
Mondo ID	MONDO:0004753
DOID	DOID:9306
ICD-10-CM	H50.6
ICD-11	230827382
SNOMED CT	5371001
UMLS	C0152223
MedGen	101828
Is cancer (heuristic)	no

Disease family

This is a subtype of strabismus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › ocular motility disease › strabismus › mechanical strabismus

Related subtypes (10): paralytic strabismus, exotropia, conjugate gaze palsy, intermittent squint, internuclear ophthalmoplegia, hypertropia, cyclotropia, esotropia, hypotropia, monofixation syndrome

Subtypes (1): Brown syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.